. 2013 Jan 9;6:11–21. doi: 10.2147/JAA.S14743

Table 1.

Studies comparing the beclomethasone-formoterol combination with the other fixed-dose combinations

Reference	Study design	Treatments and daily dose	Results
Papi et al³¹	Double-blind RCT	Extra-fine BDP/F (400/24 μg) versus FP/S (500/100 μg)	Greater FVC change from baseline with extra-fine BDP/F as compared with FP/S (P = 0.040)
Huchon et al³⁰	Double-blind, double-dummy, RCT	Extra-fine BDP/F (400/24 μg) versus BDP + F (1000/24 μg)	Greater percentage of asthma control days with extra-fine BDP/F as compared with BDP/F (P < 0.005)
Scichilone et al³⁴	Double-blind, double-dummy, RCT	Extra-fine BDP/F (400/24 μg) versus FP/S (500/100 μg)	Significant improvement from baseline of PD₂₀MchFEV₁ was observed only with extra-fine BDP/F and not with FP/S
Müller et al⁴⁵	Real-life observational study	Extra-fine BDP/F (mean daily BDP dose 312 μg) versus BUD/F (mean daily BDP dose 590 μg) and FP/S (mean daily FP dose 675 μg)	Significantly higher percentage of patients with controlled asthma with extra-fine BDP/F as compared with BUD/F + FP/S (P = 0.031); significantly better asthma control total score, daytime symptom score and rescue medication use score with extra-fine BDP/F as compared with BUD/F + FP/S (P < 0.05)
Allegra et al⁴⁶	Real-life observational study	Extra-fine BDP/F (mean daily BDP dose 321 μg) versus BUD/F (mean daily BUD dose 715 μg) and FP/S (mean daily FP dose 720 μg)	Significantly higher percentage of patients with controlled asthma with extra-fine BDP/F as compared with BUD/F (P = 0.032) and significantly higher quality of life with extra-fine BDP/F as compared with FP/S (P = 0.018)

Abbreviations: RCT, randomized controlled trial; BDP/F, beclomethasone-formoterol; FP/S, fluticasone-salmeterol; FVC, forced vital capacity; BUD/F, budesonide/formoterol; PD₂₀MchFEV₁, provocative dose of methacholine causing 20% reduction in forced expiratory volume in one second; BUD, budesonide; BDP, beclomethasone; FP, fluticasone.